Related Experiment Video
Updated: Jul 4, 2026
07:49
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors
James A McCubrey1, Michele Milella, Agostino Tafuri
1Brody School of Medicine at East Carolina University, Department of Microbiology & Immunology, 600 Moye Boulevard, Greenville, NC 27858, USA. mccubreyj@ecu.edu
Current Opinion in Investigational Drugs (London, England : 2000)
|June 3, 2008
Summary
This review explores targeting the Raf/MEK/ERK pathway with small-molecule inhibitors for cancer treatment. Inhibiting this pathway shows promise in suppressing cancer cell growth and promoting cell death.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Mutations in growth factor receptors can lead to aberrant activation of signaling pathways like Raf/MEK/ERK in cancer.
- The Raf/MEK/ERK pathway is frequently dysregulated due to mutations in Ras (20-30% of cancers) and B-Raf (melanoma, thyroid cancer).
- This pathway significantly influences cell survival and proliferation, and its aberrant regulation contributes to malignant transformation.
Purpose of the Study:
- To review the targeting of the Raf/MEK/ERK pathway using small-molecule inhibitors.
- To discuss the potential of these inhibitors in cancer therapy.
Main Methods:
- Literature review of studies on the Raf/MEK/ERK pathway and small-molecule inhibitors.
- Analysis of the role of pathway mutations in cancer development.
- Evaluation of the therapeutic potential of targeting this pathway.
Main Results:
- Mutations in growth factor receptors and upstream regulators like Ras and B-Raf activate the Raf/MEK/ERK pathway.
- Aberrant pathway activation drives uncontrolled cell growth and malignancy.
- Small-molecule inhibitors targeting this pathway demonstrate potential for cancer treatment.
Conclusions:
- Targeting the Raf/MEK/ERK pathway is a promising strategy for cancer therapy.
- Small-molecule inhibitors offer a means to suppress cancer cell growth and induce cell death.
- Further research into Raf/MEK/ERK pathway inhibitors is warranted for effective cancer treatment.
Related Concept Videos
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...